Ann Lucena Biography and Net Worth

Director of Cerus

Ann Lucena has served as a member of our Board since August 2021. She most recently served as the Chief Executive Officer of San Ramon Regional Medical Center, an award-winning acute care hospital located in the Bay Area from April 2018 to November 2022. Ms. Lucena also served as the chairperson of the board overseeing the joint venture between John Muir Health and Tenet Healthcare. Ms. Lucena served as Chief of Staff for the President of Hospital Operations of Tenet Healthcare in Dallas, Texas from 2015 until 2018. From 2012 to 2015, Ms. Lucena served as an administrator over numerous operational departments in the San Ramon Regional Medical Center. Prior to 2012, Ms. Lucena worked in healthcare consulting, where she served a number of health systems across the U.S. She holds a B.A. in human biology and a B.A. in Spanish from Stanford University and an MBA from Harvard Business School. She currently serves on the Harvard Business School Alumni Board as well as on the boards of several hospital industry associations and not-for-profit organizations.

What is Ann Lucena's net worth?: The estimated net worth of Ann Lucena is at least $151.80 thousand as of August 22nd, 2023. Ms. Lucena owns 72,284 shares of Cerus stock worth more than $151,796 as of December 5th. This net worth approximation does not reflect any other investments that Ms. Lucena may own. Learn More about Ann Lucena's net worth.
How do I contact Ann Lucena?: The corporate mailing address for Ms. Lucena and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Ann Lucena's contact information.
Has Ann Lucena been buying or selling shares of Cerus?: Ann Lucena has not been actively trading shares of Cerus during the last ninety days. Most recently, on Tuesday, August 22nd, Ann Lucena bought 7,500 shares of Cerus stock. The stock was acquired at an average cost of $1.69 per share, with a total value of $12,675.00. Following the completion of the transaction, the director now directly owns 72,284 shares of the company's stock, valued at $122,159.96. Learn More on Ann Lucena's trading history.
Who are Cerus' active insiders?: Cerus' insider roster includes Richard Benjamin (Chief Medical Officer), Eric Bjerkholt (Director), Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Jensen (Insider), Ann Lucena (Director), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), Hua Shan (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.
Are insiders buying or selling shares of Cerus?: In the last year, insiders at the biotechnology company sold shares 13 times. They sold a total of 461,150 shares worth more than $700,809.60. The most recent insider tranaction occured on March, 13th when COO Vivek K Jayaraman sold 29,985 shares worth more than $43,478.25. Insiders at Cerus own 5.6% of the company. Learn More about insider trades at Cerus.
Information on this page was last updated on 3/13/2025.

Ann Lucena Insider Trading History at Cerus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/22/2023	Buy	7,500	$1.69	$12,675.00	72,284

Ann Lucena Buying and Selling Activity at Cerus

Cerus Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Today's Range

Now: $2.10

$1.96

$2.11

50 Day Range

MA: $1.60

$1.40

$2.10

2 Week Range

Now: $2.10

$1.12

$2.24

Volume

1,534,120 shs

Average Volume

1,403,832 shs

Market Capitalization

$403.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55